Discussing Rheumatology: Safety Of Filgotinib, And Tofacitinib In Pjia

Discussing Rheumatology: Safety of filgotinib, and tofacitinib in pJIA

The Immune-Mediated Inflammatory Disease Forum

Discussing RA: Insights into Filgotinib and Tofacitinib in RA

The Immune-Mediated Inflammatory Disease Forum

Discussing RA: Insights into Filgotinib and Tofacitinib in RA

The Immune-Mediated Inflammatory Disease Forum

Discussing Rheumatology: Tofacitinib safety and dose-switching in RA

The Immune-Mediated Inflammatory Disease Forum

Efficacy and safety of tofacitinib following inadequate response to conventional antirheumatic drugs

Annals of the Rheumatic Diseases

Rheumatology Author Prof René Westhovens: Filgotinib

The Immune-Mediated Inflammatory Disease Forum

Expert commentary: Safety and efficacy of tofacitinib in JIA | Sangeeta Sule

Medicine Matters rheumatology

Discussing Rheumatology: Tofacitinib Improves PROs

The Immune-Mediated Inflammatory Disease Forum

ORAL Surveillance Tofacitinib Safety Panel

John Sundy, MD, PhD: Pooled Safety Analysis of Filgotinib

Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR)... | RTCL.TV

Medicine RTCL TV

Discussing Rheumatology: JAK Inhibitor Monotherapy in RA

The Immune-Mediated Inflammatory Disease Forum

Discussing Rheumatology: Baricitinib Safety and Treatment Interruptions

The Immune-Mediated Inflammatory Disease Forum

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

ACR 2020 | Atul Deodhar discusses a phase 3 trial of tofacitinib in ankylosing spondylitis

Medicine Matters rheumatology

How to talk to patients about JAK inhibitor safety | Victoria Ruffing

Medicine Matters rheumatology

Tofacitinib as Monotherapy Following MTX Withdrawal in PsA: Dr. Eric Ruderman

The Last Word on JAK Inhibitor Safety & 1133 Study (1.28.2022)

JAK-Inhibition in Immune-Mediated Diseases (IMiDs)

JAK Inhibitor Safety and Efficacy - Psoriatic Arthritis Posters and Abstracts from San Diego

Annenberg Center for Health Sciences